- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06291415
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
A Multicenter, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523, a Syk Inhibitor, in Adult Subjects With Immune Thrombocytopenia
Study Overview
Status
Conditions
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Thrombotic Microangiopathies
- Purpura
- Purpura, Thrombocytopenic
- Skin Manifestations
- Thrombocytopenia
- Purpura, Thrombocytopenic, Idiopathic
- Immune Thrombocytopenia
- Blood Coagulation Disorder
- Primary Immune Thrombocytopenia
- Blood Platelet Disorder
- ITP - Immune Thrombocytopenia
Intervention / Treatment
Detailed Description
This study is a Phase 1b, open-label, multicenter, single-arm study to evaluate the safety, tolerability, and preliminary efficacy of HMPL-523 in adult subjects with primary ITP diagnosed at least 3 months prior to enrollment or randomization.
In the dose escalation stage (Part 1), subjects will receive one of 3 dose levels of HMPL-523 to determine the recommended dose of HMPL-523 for the randomized dose optimization- stage (Part 2).
At the end of Part 1, 2 dose levels will be selected to be used in the dose-optimization stage (Part 2) of the study. In Part 2 of the study, subjects will be randomized in a 1:1 ratio between the 2 dose levels to better understand the exposure/efficacy/toxicity relationship.
At the end of Part 2, the Recommended Phase 3 dose (RP3D) of HMPL-523 will be determined based on the safety, efficacy and PK data.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Nick Lawn
- Phone Number: +1-973-306-4490
- Email: 2022-523-GLOB1@hutch-med.com
Study Contact Backup
- Name: Vijay Jayaprakash, MD, PhD
- Phone Number: +1-973-306-4490
- Email: 2022-523-GLOB1@hutch-med.com
Study Locations
-
-
Victoria
-
Frankston, Victoria, Australia
- Not yet recruiting
- Peninsula Private Hospital
-
Contact:
- Huy Tran, MD
-
Principal Investigator:
- Huy Tran, MD
-
-
Western Australia
-
West Perth, Western Australia, Australia
- Not yet recruiting
- The Perth Blood Institute (PBI) Hollywood Specialist Centre
-
Contact:
- Ross Baker, MD
-
Principal Investigator:
- Ross Baker, MD
-
-
-
-
-
Düsseldorf, Germany, 40479
- Not yet recruiting
- Marien Hospital Dusseldorf
-
Contact:
- Stefanie Groepper, MD
-
Principal Investigator:
- Stefanie Groepper, MD
-
-
-
-
-
Grålum, Norway, 1714
- Not yet recruiting
- Sykehuset Ostfold Kalnes (fosta) / Osfold Hospital Trust (MSL)
-
Principal Investigator:
- Waleed Ghanima, MD
-
Contact:
- Waleed Ghanima, MD
-
-
-
-
-
Barcelona, Spain
- Not yet recruiting
- Hospital Universitari Vall d'Hebron
-
Contact:
- David Ferreiras, MD
-
Principal Investigator:
- David Ferreiras, MD
-
Barcelona, Spain, 08003
- Not yet recruiting
- Hospital del Mar Barcelona
-
Contact:
- Blanca Gonzalez, MD
-
Principal Investigator:
- Blanca Gonzalez, MD
-
Burgos, Spain, 09001
- Not yet recruiting
- University de Burgos
-
Contact:
- Jose Gonzalez Lopez, MD
-
Principal Investigator:
- Jose Gonzalez Lopez, MD
-
Madrid, Spain, 28027
- Not yet recruiting
- Clinica Universidad de Navarra
-
Contact:
- Carlos Garcia Grande, MD
-
Principal Investigator:
- Carlos Garcia Grande, MD
-
Madrid, Spain, 28031
- Not yet recruiting
- Hospital Infanta Leonor
-
Contact:
- Angeles Foncillas, MD
-
Principal Investigator:
- Angeles Foncillas, MD
-
Madrid, Spain, 28007
- Not yet recruiting
- Hospital Gregorio Maranon Madrid
-
Contact:
- Cristina Izquierdo, MD
-
Principal Investigator:
- Cristina Izquierdo, MD
-
Madrid, Spain, 28040
- Not yet recruiting
- Fundacion Jimenez Diaz
-
Contact:
- Pilar Llamas Sillero, MD
-
Principal Investigator:
- Pilar Llamas Sillero, MD
-
Murcia, Spain, 30008
- Not yet recruiting
- Hospital Morales Meseguer
-
Contact:
- Maria Lozano, MD
-
Principal Investigator:
- Maria Lozano, MD
-
-
-
-
Maryland
-
Bethesda, Maryland, United States, 20817
- Recruiting
- Center for Cancer and Blood Disorders
-
Contact:
- Ralph V Boccia, MD
-
Principal Investigator:
- Ralph V Boccia, MD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Not yet recruiting
- Massachusetts General Hospital
-
Contact:
- David J Kuter, MD
-
Principal Investigator:
- David J Kuter, MD
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Not yet recruiting
- Taussig Cancer Institute
-
Contact:
- Alan Lichtin, MD
-
Principal Investigator:
- Alan Lichtin, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjects may be enrolled in this study only if they satisfy all the following criteria:
- Adult male or female subjects ≥18 years of age
- Diagnosis of ITP, with a duration of disease of at least 3 months prior to randomization or enrollment
- Intolerance or insufficient response or recurrence after at least 1 prior ITP treatment (excluding splenectomy)
- Response (defined as achieved a platelet count ≥50 × 109/L) to at least 1 prior ITP therapy (including splenectomy)
- Adequate hematologic, hepatic and renal function
Exclusion Criteria:
Subjects are not eligible for enrollment into this study if any one of the following criteria are met:
- Evidence of the presence of secondary causes of ITP
- Clinically serious hemorrhage requiring immediate adjustment of platelets
- Known history of vital organ transplantation or hematopoietic stem-cell transplantation or chimeric antigen receptor T-cells (CAR-T) therapy
- Splenectomy within 12 weeks prior to enrollment
- Presence of active malignancy unless deemed cured by adequate treatment.
- History of serious cardiovascular disease corrected QT interval (QTcF) ≥450 ms
- Uncontrolled hypertension
- Being unsuitable to participate in this study as considered by investigators
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose escalation
Part 1 will consist of the following 3 dose levels: 300, 400, and 500 mg once daily (QD).
|
Syk inhibitor
|
Experimental: Dose optimization stage
In part 2 subjects will be randomized in a 1:1 ratio between the 2 dose levels selected at the end of part 1.
|
Syk inhibitor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of HMPL-523 in adult subjects with primary ITP
Time Frame: week 1 - week 24
|
Calculated as the number and percent incidence of participants experiencing adverse events (AE).
|
week 1 - week 24
|
Dose Limiting Toxicities
Time Frame: week 1 - week 4
|
Defined as an adverse event AE that meets protocol defined Dose Limiting Toxicities (DLT) criteria during the DLT assessment window (first 28 days), unless clearly unrelated to ITP drugs.
|
week 1 - week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax (maximum plasma drug concentration)
Time Frame: week 1 and week 3
|
Blood samples will be obtained from all patients to determine maximum plasma drug concentration of HMPL-523 and metabolite M
|
week 1 and week 3
|
AUCtau (area under the concentration-time curve over a dosage interval)
Time Frame: week 1 and week 3
|
Blood samples will be obtained from all patients to determine area under the concentration time curve over periodic dosing intervals for HMPL-523 and metabolite M1
|
week 1 and week 3
|
Tmax (time to reach maximum plasma drug concentration)
Time Frame: week 1 and week 3
|
Blood samples will be obtained from all patients to determine time to reach maximum plasma concentration of HMPL-523 and metabolite M1
|
week 1 and week 3
|
Cmin (minimum plasma drug concentration)
Time Frame: week 1 - week 20
|
Blood samples will be obtained from all patients to determine minimum plasma concentration of HMPL-523 and metabolite M1
|
week 1 - week 20
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Vijay Jayaprakash, MD, PhD, Hutchmed
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cytopenia
- Hemostatic Disorders
- Blood Coagulation Disorders
- Hemorrhage
- Purpura
- Purpura, Thrombocytopenic
- Thrombotic Microangiopathies
- Hematologic Diseases
- Purpura, Thrombocytopenic, Idiopathic
- Hemorrhagic Disorders
- Thrombocytopenia
- Autoimmune Diseases
- Immune System Diseases
- Pathologic Processes
- Skin Manifestations
- Blood Platelet Disorders
Other Study ID Numbers
- 2022-523-GLOB1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pathologic Processes
-
GuerbetCompletedPathological ProcessesUnited States
-
Philips Digital & Computational PathologyCompleted
-
Institut Claudius RegaudWest Cancerology Institute, France; Toulouse Capitole UniversityRecruiting
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
University Hospital, ToulouseCompletedPlatelet DysfunctionFrance
-
Actavis Inc.Completed
-
Ranbaxy Laboratories LimitedCompletedHealthyUnited States
-
Ranbaxy Laboratories LimitedCompleted
-
Ranbaxy Laboratories LimitedCompleted
-
Ranbaxy Laboratories LimitedCompleted
Clinical Trials on HMPL-523
-
HutchmedActive, not recruitingImumune Thrombocytopenia(ITP) Human Mass BalanceChina
-
Hutchison Medipharma LimitedCompletedRheumatoid Arthritis (RA)Australia
-
Hutchison Medipharma LimitedUnknownMature B-cell NeoplasmsChina
-
Hutchison Medipharma LimitedIqvia Pty LtdUnknownHematologic MalignanciesAustralia
-
HutchmedActive, not recruitingNon Hodgkin LymphomaSpain, United States, Denmark, France, Finland, Italy, Poland
-
Hutchison Medipharma LimitedActive, not recruiting
-
Hutchison Medipharma LimitedUnknownImmune Thrombocytopenia (ITP)China
-
Hutchison Medipharma LimitedActive, not recruitingWarm Antibody Autoimmune Hemolytic AnemiaChina
-
Hutchison Medipharma LimitedCompleted
-
Hutchison Medipharma LimitedTerminatedAcute Myeloid LeukemiaChina